Retrospective Clinical Data Collection on Carbomedics OptiForm Mitral Heart Valve

NCT05898230 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-03-07

No results posted yet for this study

Summary

The objective of this study is to evaluate the medium- to long-term safety of the Carbomedics OptiForm Mitral Heart Valve after the implantation for mitral valve disease in the Chinese population.

The study is designed as a post-market, retrospective, single arm and multicentric data collection

Conditions

  • Mitral Valve Disease

Interventions

DEVICE

Mitral Valve Replacement

Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve

Sponsors & Collaborators

  • Corcym S.r.l

    lead INDUSTRY

Principal Investigators

  • Sara Gaggianesi · Corcym S.r.l

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-23
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05898230 on ClinicalTrials.gov